SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Evel Knievel — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEvel Knievel
Date of birth1938-10-17
IdentifiersMRN HR-RB001-SYN-TD; SSN (made up) 000-01-4927
Document date1996-01-26
AuthorDale Rasmussen, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Hepatitis C results and hepatology consultation. [S]

History of Present Illness

Mr. Knievel returns two weeks after his first visit. The hepatitis C antibody was positive and the reflex test found HCV RNA, 2.35 million IU/mL, genotype 1a. Hepatitis B surface antigen, core antibody and surface antibody were all negative, so he has never had hepatitis B and is not immune; hepatitis A IgG was negative; HIV was negative. The ultrasound a week ago showed a nodular liver, a 14.2 cm spleen, no liver mass and no ascites. Dr. Okonkwo of hepatology saw him this morning, and transient elastography in her clinic measured liver stiffness at 26.8 kPa. He stopped ibuprofen and omeprazole after the first visit and uses acetaminophen twice a day and diclofenac gel on his knees; pain is a little worse in the mornings. He has cut down to about two drinks most evenings. He has had no abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. He has had no thoughts of self-harm. [S]

ElementDetail
Hepatitis CAntibody positive; HCV RNA 2.35 million IU/mL; genotype 1a; never treated
Other serologyHepatitis B: not infected, not immune. Hepatitis A: not immune. HIV negative
StagingFIB-4 4.94; liver stiffness 26.8 kPa; nodular liver and 14.2 cm spleen on ultrasound; platelets 118
Liver functionBilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, no ascites or encephalopathy: Child-Pugh A5; MELD-Na 8
AlcoholCut down to about two drinks most evenings

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for months; no fever or weight loss
GastrointestinalNegativeNo abdominal swelling, black stools or vomiting of blood
IntegumentaryPositiveSmall red spots on the chest; no yellowing or itching
NeurologicalNegativeNo confusion, sleep reversal or tremor
MusculoskeletalPositiveHip, knee and back pain, 6 of 10, worse in the mornings since stopping ibuprofen
PsychiatricPositiveWorried about the diagnosis; PHQ-9 6; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route1991-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route1994-06-01 to 1996-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route1994-06-01 to 1996-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route1996-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route1996-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26 to 1996-02-23completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1996-01-26Body height178cmS
1996-01-26Body weight85.6kgS
1996-01-26Body mass index (BMI) [Ratio]27kg/m2S
1996-01-26Systolic blood pressure136mm[Hg]S
1996-01-26Diastolic blood pressure82mm[Hg]S
1996-01-26Heart rate78/minS
1996-01-26Respiratory rate14/minS
1996-01-26Body temperature36.7CelS
1996-01-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1996-01-26Liver stiffness by US.transient elastography26.8kPaBelow 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertensionHighS
1996-01-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1996-01-26Total score [AUDIT-C]4{score}S
1996-01-26Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S

Physical Exam

Vital signs recorded on 1996-01-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 85.6 kg; blood pressure 136/82, pulse 78
EyesNo scleral icterus
SkinSix spider angiomas on the chest and shoulders; palmar erythema; no jaundice or bruising
AbdomenLiver edge firm, 2 cm below the costal margin; spleen tip palpable; no shifting dullness
ExtremitiesNo leg swelling
FeetMonofilament sensation intact; pulses present; no ulcers
NeurologicalNo asterixis; oriented

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1962 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cactiveconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHepatitis C antibody with reflex HCV RNA and genotypeAt diagnosisUp to dateAntibody positive; HCV RNA 2.35 million IU/mL; genotype 1a (first-visit sample)
LaboratoryHepatitis B surface antigen, core antibody and surface antibodyBefore any HCV treatmentUp to dateAll negative: no reactivation risk; vaccinate
LaboratoryHIV and hepatitis A IgGBefore HCV treatmentUp to dateHIV negative; hepatitis A not immune
LaboratoryFIB-4At diagnosisUp to date4.94 from the first-visit results (age 57, AST 96, ALT 88, platelets 118): cirrhosis likely
ImagingTransient elastographyAt diagnosisCompleted today26.8 kPa: cirrhosis with clinically significant portal hypertension
ImagingLiver ultrasoundWithin six months before treatment; every six months in cirrhosisUp to dateA week ago: nodular liver, splenomegaly, no mass, no ascites
ExaminationChild-Pugh class and MELD-NaAt diagnosis and every six months in cirrhosisCompleted todayChild-Pugh A5; MELD-Na 8
ExaminationSigns of decompensation (ascites, encephalopathy, jaundice, bleeding)Each visit in cirrhosisCompleted todayNone
Medication safetyDrug interaction review before HCV treatmentBefore treatmentCompleted todayOmeprazole and ibuprofen stopped; atorvastatin allowed with monitoring; no amiodarone; no herbal supplements
Medication safetyNon-selective beta-blocker for clinically significant portal hypertensionStart, then titrate to blood pressure and heart rateCompleted todayCarvedilol 6.25 mg daily started
ExaminationScreening endoscopy for varicesOnly if a beta-blocker cannot be takenNot indicatedHe takes carvedilol, so Baveno VII does not call for screening endoscopy
Medication safetyHepatitis A and B vaccinationAt diagnosis of chronic liver disease if not immuneCompleted todayHepatitis A dose 1 and hepatitis B (CpG-adjuvanted) dose 1 today
LaboratoryA1c and glucose monitoring in cirrhosisEvery three months when not at goalUp to dateA1c 7.4% in January; continuous glucose monitor ordered because the A1c can read falsely low
ExaminationDiabetic foot examinationYearlyCompleted todayMonofilament sensation and pulses normal
ReferralDiabetic eye examinationYearlyReferredReferred; last examination over three years ago
Medication safetyStatin for diabetesAge 40 to 75 with diabetesCompleted todayAtorvastatin 20 mg started; safe in compensated cirrhosis
SurveyAlcohol use (AUDIT-C)Each visit in liver diseaseCompleted todayAUDIT-C 4: cutting down; goal is no alcohol
SurveyPain score and functionEach visitCompleted today6 of 10 after stopping ibuprofen; acetaminophen up to 2 g a day and topical diclofenac
ReferralHepatologyAt diagnosis of hepatitis C with cirrhosisCompleted todaySeen this morning; recommendations in the consultation note
SurveyDepression screen (PHQ-9)At diagnosis and when treatment changesCompleted todayPHQ-9 6; no thoughts of self-harm

Goal progress:

Immunizations given today: Hepatitis A vaccine, adult, dose 1 of 2; Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 1 of 2 [S]

Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Physical therapy assessment next week. Antiviral treatment to start at the next visit in four weeks, with the second hepatitis B dose and carvedilol titration. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. Next scheduled visit 1996-02-23: day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density plan. [S]